Stock BHVN BIOHAVEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Biohaven Ltd.

Equities

BHVN

VGG1110E1079

End-of-day quote Nyse
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
35.1 USD -0.37% Intraday chart for Biohaven Ltd. -4.41% -17.99%
May. 29 Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day CI
May. 29 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors CI

Evolution of the average Target Price on Biohaven Ltd.

Price target over the last 5 years

History of analyst recommendation changes

dba8ddad4e8e.K0GjLgbi2p5CJmB1iOMNGZ4Rvy0W4588FKsNXmSlKo8.GyrKX2enjcQISgg914BIXPR7jh9CgftmUON3FiP9c_xKc5FDXI3t-Hd0Ew~acf1abe79d7057ea481df47e23b9f522

Analyst Recommendations on Biohaven Ltd.

Biohaven Insider Bought Shares Worth $512,877, According to a Recent SEC Filing MT
Biohaven Insider Bought Shares Worth $1,002,470, According to a Recent SEC Filing MT
Biohaven Insider Bought Shares Worth $999,169, According to a Recent SEC Filing MT
Biohaven Launches $200 Million Common Stock Offering MT
BTIG Starts Biohaven Pharmaceutical Holding at Buy With $24 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
35.1 USD
Average target price
56.89 USD
Spread / Average Target
+62.08%
High Price Target
66 USD
Spread / Highest target
+88.03%
Low Price Target
50 USD
Spread / Lowest Target
+42.45%

Consensus detail

Consensus revision (last 18 months)

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BHVN Stock
  4. Consensus Biohaven Ltd.